Celldex Therapeutics Acquires Kolltan Pharmaceuticals 2016

Celldex Therapeutics announced its acquisition of Kolltan Pharmaceuticals in November 2016, integrating Kolltan's clinical-stage immuno-oncology programs targeting receptor tyrosine kinases (RTKs). The combination aims to strengthen Celldex's pipeline with novel anti-KIT and anti-ErbB3 antibody-based therapies to overcome tumor resistance mechanisms in cancer patients.